Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The calcium pump PMCA4b promotes epithelial cell polarization and lumen formation.
Commun Biol
March 2025
Department of Transfusion Medicine, Semmelweis University, Budapest, Hungary.
Loss of epithelial cell polarity and tissue disorganization are hallmarks of carcinogenesis, in which Ca signaling plays a significant role. Here we demonstrate that the plasma membrane Ca pump PMCA4 (ATP2B4) is downregulated in luminal breast cancer, and this is associated with shorter relapse-free survival in patients with luminal A and B1 subtype tumors. Using the MCF-7 breast cancer cell model we show that PMCA4 silencing results in the loss of cell polarity while a forced increase in PMCA4b expression induces cell polarization and promotes lumen formation.
View Article and Find Full Text PDFThe feedback loop between miR-222-3p and ZEB1 harnesses metastasis in renal cell carcinoma.
Cell Death Discov
March 2025
Department of Urology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Renal cell carcinoma (RCC) is an aggressive malignancy originating from the renal parenchyma, often leading to high mortality due to local invasion and distant metastasis. MicroRNAs (miRNAs) play essential roles in RCC progression. Through miRNA sequencing, we identified significant upregulation of miR-222-3p in metastatic RCC tissues.
View Article and Find Full Text PDFNon-invasive Lobular Neoplasia: Review and Updates.
Semin Diagn Pathol
March 2025
Department of Pathology, Baptist Hospital of Miami, Baptist Health System, Miami, FL, USA.
Non-invasive lobular neoplasia (LN) encompasses atypical lobular hyperplasia (ALH), classic lobular carcinoma in situ (CLCIS), florid lobular carcinoma in situ (FLCIS), and pleomorphic lobular carcinoma in situ (PLCIS). Lobular neoplasia is a neoplastic epithelial proliferation of the terminal duct lobular unit. A defining feature is discohesion due to the loss of E-cadherin, a protein that facilitates cell-to-cell adhesion.
View Article and Find Full Text PDFEffects of PARP1 inhibitor PJ-34 on TGFα, IL-6, and IL-1β levels in diabetic nephropathy.
J Immunol
February 2025
Orthopedics Department, Central Hospital of Ezhou, Ezhou, China.
Diabetic nephropathy is a severe chronic complication characterized by cytotoxicity, inflammation, and fibrosis, ultimately leading to renal failure. This study systematically investigated the effects of the PARP1 inhibitor PJ-34 on high glucose-induced cytotoxicity, inflammation, and fibrosis in HK-2 cells, as well as its improvement on neuropathic pain response and transforming growth factor β (TGFβ) expression in a type 1 diabetes mellitus diabetic nephropathy mouse model. Through cellular and animal experiments, we observed that PJ-34 significantly enhanced the proliferative capacity of cells damaged by high glucose, reduced apoptosis, and decreased the release of proinflammatory factors TGFα, interleukin-6, and interleukin-1β.
View Article and Find Full Text PDFMicrofluidic isolation and release of live disseminated breast tumor cells in bone marrow.
PLoS One
March 2025
Department of Mechanical and Aerospace Engineering, Interdisciplinary Microsystems Group, Gainesville, Florida, United States of America.
Breast cancer represents a significant therapeutic challenge due to its aggressive nature and resistance to treatment. A major cause of treatment failure in breast cancer is the presence of rare, low-proliferative disseminated tumor cells (DTCs) in distant organs including the bone marrow. This study introduced a microfluidic-based approach to improve the immunodetection and isolation of these rare DTCs for downstream analysis, with an emphasis on optimizing immunocapture, release, and enrichment methods of live DTCs as compared to the standard approach for blood-borne circulating tumor cells (CTCs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!